Annual CFF
-$1.61 M
-$129.09 M-101.27%
31 December 2023
Summary:
Xeris Biopharma Holdings annual cash flow from financing activities is currently -$1.61 million, with the most recent change of -$129.09 million (-101.27%) on 31 December 2023. During the last 3 years, it has fallen by -$127.68 million (-101.28%). XERS annual CFF is now -101.26% below its all-time high of $128.21 million, reached on 31 December 2018.XERS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$83.00 K
-$742.00 K-112.59%
30 September 2024
Summary:
Xeris Biopharma Holdings quarterly cash flow from financing activities is currently -$83.00 thousand, with the most recent change of -$742.00 thousand (-112.59%) on 30 September 2024. Over the past year, it has dropped by -$11.00 thousand (-15.28%). XERS quarterly CFF is now -100.09% below its all-time high of $90.80 million, reached on 30 June 2018.XERS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$34.54 M
-$11.00 K-0.03%
30 September 2024
Summary:
Xeris Biopharma Holdings TTM cash flow from financing activities is currently $34.54 million, with the most recent change of -$11.00 thousand (-0.03%) on 30 September 2024. Over the past year, it has dropped by -$14.24 million (-29.20%). XERS TTM CFF is now -78.44% below its all-time high of $160.16 million, reached on 31 March 2019.XERS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XERS Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -101.3% | -15.3% | -29.2% |
| 3 y3 years | -101.3% | -8400.0% | +13.4% |
| 5 y5 years | -101.3% | -100.4% | -56.0% |
XERS Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -101.3% | at low | -100.1% | +93.3% | -72.9% | +2241.1% |
| 5 y | 5 years | -101.3% | at low | -100.1% | +93.3% | -74.3% | +2241.1% |
| alltime | all time | -101.3% | at low | -100.1% | +93.3% | -78.4% | +2241.1% |
Xeris Biopharma Holdings Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$83.00 K(-112.6%) | $34.54 M(-0.0%) |
| June 2024 | - | $659.00 K(-98.1%) | $34.55 M(+0.3%) |
| Mar 2024 | - | $35.19 M(-2952.0%) | $34.44 M(-2235.4%) |
| Dec 2023 | -$1.61 M(-101.3%) | -$1.23 M(+1613.9%) | -$1.61 M(-103.3%) |
| Sept 2023 | - | -$72.00 K(-112.9%) | $48.78 M(+0.2%) |
| June 2023 | - | $556.00 K(-164.4%) | $48.66 M(+0.5%) |
| Mar 2023 | - | -$863.00 K(-101.8%) | $48.42 M(-62.0%) |
| Dec 2022 | $127.47 M(+367.8%) | $49.16 M(<-9900.0%) | $127.47 M(+62.5%) |
| Sept 2022 | - | -$187.00 K(-160.3%) | $78.44 M(-0.2%) |
| June 2022 | - | $310.00 K(-99.6%) | $78.63 M(-0.2%) |
| Mar 2022 | - | $78.19 M(>+9900.0%) | $78.78 M(+189.1%) |
| Dec 2021 | $27.25 M(-78.4%) | $125.00 K(>+9900.0%) | $27.25 M(-10.5%) |
| Sept 2021 | - | $1000.00(-99.8%) | $30.45 M(-30.0%) |
| June 2021 | - | $460.00 K(-98.3%) | $43.51 M(-61.4%) |
| Mar 2021 | - | $26.66 M(+701.6%) | $112.66 M(-10.6%) |
| Dec 2020 | $126.06 M | $3.33 M(-74.5%) | $126.06 M(+1.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | $13.06 M(-81.2%) | $124.71 M(-7.1%) |
| June 2020 | - | $69.61 M(+73.7%) | $134.22 M(+108.2%) |
| Mar 2020 | - | $40.07 M(+1933.9%) | $64.45 M(-20.0%) |
| Dec 2019 | $80.53 M(-37.2%) | $1.97 M(-91.3%) | $80.53 M(+2.5%) |
| Sept 2019 | - | $22.57 M(<-9900.0%) | $78.59 M(+13.6%) |
| June 2019 | - | -$157.00 K(-100.3%) | $69.20 M(-56.8%) |
| Mar 2019 | - | $56.15 M(>+9900.0%) | $160.16 M(+24.9%) |
| Dec 2018 | $128.21 M(+264.9%) | $29.00 K(-99.8%) | $128.21 M(-4.1%) |
| Sept 2018 | - | $13.18 M(-85.5%) | $133.65 M(+10.9%) |
| June 2018 | - | $90.80 M(+275.1%) | $120.48 M(+101.8%) |
| Mar 2018 | - | $24.20 M(+342.7%) | $59.71 M(+69.9%) |
| Dec 2017 | $35.14 M(+800.1%) | $5.47 M(>+9900.0%) | $35.14 M(+18.4%) |
| Sept 2017 | - | $19.00 K(-99.9%) | $29.67 M(+0.1%) |
| June 2017 | - | $30.02 M(-8257.9%) | $29.65 M(-8157.9%) |
| Mar 2017 | - | -$368.00 K | -$368.00 K |
| Dec 2016 | $3.90 M | - | - |
FAQ
- What is Xeris Biopharma Holdings annual cash flow from financing activities?
- What is the all time high annual CFF for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings annual CFF year-on-year change?
- What is Xeris Biopharma Holdings quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings quarterly CFF year-on-year change?
- What is Xeris Biopharma Holdings TTM cash flow from financing activities?
- What is the all time high TTM CFF for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings TTM CFF year-on-year change?
What is Xeris Biopharma Holdings annual cash flow from financing activities?
The current annual CFF of XERS is -$1.61 M
What is the all time high annual CFF for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high annual cash flow from financing activities is $128.21 M
What is Xeris Biopharma Holdings annual CFF year-on-year change?
Over the past year, XERS annual cash flow from financing activities has changed by -$129.09 M (-101.27%)
What is Xeris Biopharma Holdings quarterly cash flow from financing activities?
The current quarterly CFF of XERS is -$83.00 K
What is the all time high quarterly CFF for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high quarterly cash flow from financing activities is $90.80 M
What is Xeris Biopharma Holdings quarterly CFF year-on-year change?
Over the past year, XERS quarterly cash flow from financing activities has changed by -$11.00 K (-15.28%)
What is Xeris Biopharma Holdings TTM cash flow from financing activities?
The current TTM CFF of XERS is $34.54 M
What is the all time high TTM CFF for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high TTM cash flow from financing activities is $160.16 M
What is Xeris Biopharma Holdings TTM CFF year-on-year change?
Over the past year, XERS TTM cash flow from financing activities has changed by -$14.24 M (-29.20%)